
("
Sol Skin Cancer Technology
Successful Results of Sensitisation Study
Sol is a proprietary topical formulation designed to deliver into the skin an active known to prevent the formation of solar (actinic) keratosis and skin cancer.
The study, conducted by
Formerly, studies carried out in collaboration between
Sol's "non-irritancy" was found to be comparable to baby sun protection products tested previously, with Sol scoring better those products which they would define as "very mild".
The Company is delighted with the results, which demonstrate that Sol is "non-irritant". The comfort and safety of human skin's reaction to the topical application of Sol is a further valuable marker of the asset and this technology.
These results add to the data announced on
Commenting on the announcement, Chairman,
"This additional positive data on Sol, greatly enhances the product's overall profile and supports our ongoing negotiations with potential commercial partners."
This announcement contains inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 ("MAR").
The directors of the Company take responsibility for this announcement.
For further enquiries:
|
+44 (0) 7831 675747
+44 (0) 7747 625506
+44 (0) 7776 234600 |
|
|
AQSE Corporate Adviser: |
+44 (0) 20 7213 0880 |
|
|
Broker: |
+44 (0) 20 3815 8880 |
Notes to Editors:
The Company's current lead product and focus is Sol, a potentially innovative topical product for the treatment of solar keratosis and the prevention of skin cancers.
The Company originated from the
For more information on the Company please visit: www.incanthera.com
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the